{"id":"air-dnase","safety":{"commonSideEffects":[{"rate":null,"effect":"Respiratory tract irritation"},{"rate":null,"effect":"Cough"},{"rate":null,"effect":"Hemoptysis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"The drug breaks down DNA present in sputum and mucus secretions, which contributes to the thick, sticky consistency that obstructs airways in cystic fibrosis patients. By enzymatically degrading this extracellular DNA, AIR DNase reduces mucus viscosity and improves mucociliary clearance, potentially enhancing lung function and reducing respiratory infections.","oneSentence":"AIR DNase is a recombinant human deoxyribonuclease that degrades extracellular DNA to reduce mucus viscosity and improve airway clearance in cystic fibrosis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:21:20.364Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cystic fibrosis"}]},"trialDetails":[{"nctId":"NCT02722122","phase":"PHASE2","title":"Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of AIR DNase™in Patients With Cystic Fibrosis Previously Treated With Pulmozyme®","status":"UNKNOWN","sponsor":"Protalix","startDate":"2016-05","conditions":"Cystic Fibrosis","enrollment":15},{"nctId":"NCT02605590","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics Study of AIR DNAse Administered by Inhalation to Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Protalix","startDate":"2015-12","conditions":"Cystic Fibrosis (CF)","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":52,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AIR DNase","genericName":"AIR DNase","companyName":"Protalix","companyId":"protalix","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AIR DNase is a recombinant human deoxyribonuclease that degrades extracellular DNA to reduce mucus viscosity and improve airway clearance in cystic fibrosis. Used for Cystic fibrosis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}